Notifications
Clear all
Immunotherapy
1
Posts
1
Users
2
Likes
740
Views
Topic starter
30/05/2021 9:26 pm
From the abstract: ''Here, we show that therapeutically targeting the COX-2/PGE2/EP2-4 pathway with widely used non-steroidal and steroidal anti-inflammatory drugs synergized with ICB (immune checkpoint blockade) in mouse cancer models.'' https://cancerdiscovery.aacrjournals.org/content/early/2021/05/25/2159-8290.CD-20-1815 https://cancerdiscovery.aacrjournals.org/content/candisc/early/2021/05/25/2159-8290.CD-20-1815.full.pdf
The authors of the paper cite retrospective studies which suggest that NSAIDs may enhance progression-free survival and/or overall survival of patients receiving ICB https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0518 https://jitc.bmj.com/content/8/2/e000889
Also, addition studies, which showed that the overall response rate (tumour shrinkage) of patients who discontinued ICB and received corticosteroids was similar, and in some cases even higher, than that of patients maintained on ICB https://ascopubs.org/doi/full/10.1200/JCO.2017.73.2289 https://ascopubs.org/doi/full/10.1200/JCO.2016.72.1167 https://ascopubs.org/doi/full/10.1200/JCO.2015.60.8448 https://ascopubs.org/doi/full/10.1200/JCO.2015.66.1389
